Clinical trialNo phase (not a drug trial)Withdrawn
Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
- Outcome
- Stopped earlystudy PI no longer at Institution (Other)
- Phase
- No phase (not a drug trial)
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 1 January 2022
- Planned end
- 31 December 2023
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 24 February 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.